Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine vs Placebo in Children and Adolescents with ADHD and Comorbid ODD
NCT00406354Phase 4Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2006
- Primary completion
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of atomoxetine in attention deficit hyperactivity disorder (ADHD) and oppositional defiant disorder (ODD) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Swanson, Nolan and Pelham Rating Scale Revised (SNAP-IV) Oppositional Defiant Disorder Subscale Score at 9 weeks. Started Nov 2006; status: completed.
02
Drugs
atomoxetine
03
Conditions
attention deficit hyperactivity disorder (ADHD)oppositional defiant disorder (ODD)
Beyond the preview
Go deeper on NCT00406354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00406354.